The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
IP: Use at 2 - 5 µg/mg of lysate.
WB: 1/5000 - 1/15000. Detects a band of approximately 35 kDa (predicted molecular weight: 31 kDa).
Not yet tested in other applications.
Optimal dilutions/concentrations should be determined by the end user.
Involved in lineage commitment of primary hemopoietic progenitors by restricting erythroid formation and enhancing myeloid formation. Interferes with erythropoietin-induced erythroid terminal differentiation by preventing cells from exiting the cell cycle through suppression of CDKN1B/p27Kip1 levels. Suppresses RFWD2/COP1 activity via CSN3 which activates p53 and induces cell cycle arrest. Binds DNA and affects the expression of a number of genes so may function as a transcription factor in the nucleus.
Most abundant in testis, ovary, skeletal muscle, heart, kidney and colon. Low expression in spleen, thymus and peripheral blood leukocytes.
Involvement in disease
Note=A chromosomal aberration involving MLF1 is a cause of myelodysplastic syndrome (MDS). Translocation t(3;5)(q25.1;q34) with NPM1/NPM.
Belongs to the MLF family.
Phosphorylation is required for binding to YWHAZ.
Cytoplasm. Nucleus. In non-hematopoietic cells, resides primarily in the cytoplasm with some punctate nuclear localization. Shuttles between the cytoplasm and nucleus. In hematopoietic cells, located preferentially in the nucleus. Found in the nucleolus when fused to NPM.
Detection of Human Myeloid leukemia factor 1 by Immunoprecipitation in Whole cell lysate from HeLa cells (1 mg for IP, 1/4 of IP loaded).
Affinity purified rabbit anti-Myeloid leukemia factor 1 antibody (ab70211) was used at 3 µg/mg lysate for IP (Lane 1) and at 0.1 µg/ml for WB detection. Lane 2 represents IP IgG control.